Vaccines, Blood & Biologics

Regulatory Information about Biologics Advertising & Promotional Labeling

Food and Drug Administration Amendments Act of 2007 (FDAAA)

(Some of the links on this page take you to the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Code of Federal Regulations on other government Web sites. Once you leave this page, click the back button on your browser to return to the FDA Web site.) 

On September 27, 2007, President Bush signed into law the Food and Drug Administration Amendments Act of 2007 (FDAAA) which includes the reauthorization and expansion of the Prescription Drug User Fee Act (PDUFA).

The FDA may require the submission of any television advertisement for a drug for review before dissemination of the television advertisement, under Sec. 901 of Title IX of FDAAA, which also contains a number of other provisions related to DTC advertising, including civil monetary penalties for violative DTC ads (amends § 303 of FDCA).  Any person who disseminates or causes another party to disseminate a false or misleading DTC ad shall be liable for a civil penalty of up to $250,000 for the first violation, and up to $500,000 for subsequent violations in a 3 year period.

For more details on FDAAA and PDUFA, refer to:


Contact FDA

Advertising and Promotional Labeling Branch (APLB)

Office of Compliance and Biologics Quality

Center for Biologics Evaluation and Research

Food and Drug Administration

1093 New Hampshire Avenue

WO Building 71

Silver Spring, MD 20993

Page Last Updated: 06/18/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English